Asia Pacific Typhoid Fever Vaccines Market Overview and Growth by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Asia Pacific Typhoid Fever Vaccines Market Forecast to 2027 - Covid-17 Impact and Regional Analysis by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine and Others) and Route of administration (Oral and Injectable) and Country

  • Report Date : Nov 2020
  • Report Code : TIPRE00016285
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 90
Page Updated: Feb 2021

The Asia Pacific typhoid fever vaccines  market is expected to reach US$ 135.79 million in 2027 from US$ 64.75  million in 2019. The market is estimated to grow with a CAGR of 10.0%from 2020-2027.



Key factors that are driving growth of the market are rising prevalence of typhoid, and increase in support for typhoid immunization. However, side-effects associated with typhoid fever vaccines hinder the Asia Pacific Typhoid Fever Vaccines market growth.

Typhoid fever is the most common bacterial infection among the Asian countries. Enteric fever is transmitted through contaminated food and water with human waste. Due to poor sanitation facilities in Asian countries, the prevalence of typhoid in Asian countries is high.

According to the recent estimates of the World Health Organization (WHO), typhoid is an endemic fever in Africa, Asia, Latin America, Oceania, and the Caribbean. The WHO also states that 80% of the typhoid fever cases arise from India, Bangladesh, China, Laos, Nepal, Indonesia, Vietnam, and Pakistan.

Furthermore, as per the study ‘Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities’ published in 2019, about seven million people are infected with typhoid each year in South Asia with around 75 000 deaths.  As per the recent study by the All India Institute of Medical Sciences (AIIMS), around 494 per 100,000 children of age group 5–15 years suffered from typhoid in 2017.

Thus, the growing incidence of enteric fever (typhoid) in Asian countries is likely to drive the demand for typhoid vaccines in Asian countries during the forecast period.

Furthermore, Countries in the Asia Pacific are facing challenges due to increasing incidences of COVID-19. As per the data of Worldometer, as of counts as of October 06, 2020, China reported 85,482 COVID-19 cases, while in Japan, it stood at 85,739, India recorded 6,685,082 cases, and Australia reported 27,173 confirmed cases. In India, which reported a new daily high of 70,000 cases, nearly a dozen states have imposed a partial lockdown in high-risk areas. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission.

Rest of Asia Pacific Typhoid Fever Vaccines  Market Revenue and Forecast to 2027 (US$ Mn)

Rest of Asia Pacific Typhoid Fever Vaccines  Market Revenue and Forecast to 2027 (US$ Mn)
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Asia Pacific Typhoid Fever Vaccines  – Market Segmentation

By Vaccine Type

  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
  • Others

By Route of Administration

  • Oral
  • Injectable

By Country

  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Rest of Asia Pacific

Company Profiles

  • GlaxoSmithKline plc
  • Shanghai institute of biological products co. Ltd.
  • PT Bio Farma
  • BIO-MED
  • BHARAT BIOTECH

Asia Pacific Typhoid Fever Vaccines Report Scope

Report Attribute Details
Market size in 2019 US$ 64.75 Million
Market Size by 2027 US$ 135.79 Million
Global CAGR (2020 - 2027) 10.0%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Vaccine Type
  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
By Route of administration
  • Oral and Injectable
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • GlaxoSmithKline plc
  • Shanghai institute of biological products co., Ltd
  • PT Bio Farma
  • BIO-MED
  • BHARAT BIOTECH
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
ISO Certified Logo